Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
about
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cellsNONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell linesInterferon regulatory factor 1 transactivates expression of human DNA polymerase η in response to carcinogen N-methyl-N'-nitro-N-nitrosoguanidineAdvances in drug delivery system for platinum agents based combination therapyNoble metals in oncologyStructure and mechanism of human DNA polymerase ηFlanking Bases Influence the Nature of DNA Distortion by Platinum 1,2-Intrastrand (GG) Cross-LinksStructural basis of human DNA polymerase η-mediated chemoresistance to cisplatin.Anticancer activity of methyl-substituted oxaliplatin analogs.Experimental and theoretical investigations of the self-association of oxaliplatin.Real-time monitoring of cisplatin-induced cell death.Synergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathwayERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsSafety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesUnusual DNA binding modes for metal anticancer complexes.Structural basis for the inefficient nucleotide incorporation opposite cisplatin-DNA lesion by human DNA polymerase β.Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance.Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implicationsIdentification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approachSequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair proteinChemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo.DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents.Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy.What a difference a decade makes: insights into translesion DNA synthesis.Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes.On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapyTranslesion DNA polymerases and cancerWEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistancePredicting of Effective Dose as Biomarker for Cytotoxicity Using Partial Least Square-Fourier Transform Infrared Spectroscopy (PLS_FTIR).Assessment of the proliferation status of glioblastoma cell and tumour tissue after nanoplatinum treatment.Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer.Therapeutic interventions to disrupt the protein synthetic machinery in melanoma
P2860
Q21133026-66959B69-FC62-4089-980A-90009DEAB9E5Q24298410-D06D264F-F664-4B73-B024-229080C78AA6Q24306282-26EB8C26-BCD1-4B52-AEEA-7980B9898595Q26771390-D64429D1-5C09-4A86-995A-342CBF9EB55DQ26777745-00B43252-ACF8-47D8-AD40-08D194155E21Q27662730-963ECF59-E43B-4BF9-B5DE-87D524B9C9B3Q27671829-37BA8DCD-4B16-489E-BB42-80C00414F198Q27678705-99776FEA-6FEA-43E5-AA93-E8B1D07E6C19Q30515979-0658D04D-3020-4421-B512-4B9818B237A0Q30830211-991DB85A-9134-49CF-8F03-0D2581300A49Q31014842-F87E3DC4-28A8-4EC5-B0E7-C1DCF92BD569Q33597926-F56284B0-A3EB-4271-8660-B3811FC5F755Q33634975-DE8F3257-9590-4692-A847-7F93591F2D8AQ33844916-79C7793B-8F9B-44D0-A8AA-43172C6FE0E6Q34008793-E9F5CCBB-C668-452D-A281-F43133251CFDQ34023788-57F41809-0A47-4FDB-ACF6-343C112693D2Q34071185-D8E33181-FECB-41BC-80BA-C434E8A148AAQ34467599-772888E4-9909-4110-88BB-1B214ED66512Q34721854-3CB1E2F3-B319-490B-A3E2-A90437753321Q34752116-6B18864B-9F41-49EC-ADA3-1C6E881457CDQ34842777-309BF844-577B-47D4-93A9-B0ECC2C8D2BEQ35041359-06A8EA6B-9A0D-443E-9441-82F70A5F4A4CQ35377658-DFEE47B5-2D3F-4854-8560-89FE602D5776Q35572923-982A8EB2-4C26-42B3-B5F6-04DD3969E6B2Q35812082-B4EC1A42-8A05-4E54-8394-31D84CE7AF14Q35836592-EDA9C7B5-D845-43AB-89AA-2D83FE76799DQ35946327-79FE9625-C616-486B-A28A-A38E1DFF98AAQ35962767-7271F4C2-0A75-432B-8AC7-3A16F2BCD948Q35965268-94D405B3-AAEA-4FE9-AC1A-ADCC10CE3AE8Q35996723-F107E7C0-AC80-4A4D-8EF3-D304D8D47082Q36013916-F33420DE-0E9E-4A59-A849-84F2DD5682EBQ36023692-5ECB6C31-45A0-4093-BD45-0B2E7692B60CQ36029514-03666E5B-B079-44C1-B64A-B91F7B6BB42EQ36107216-DCD4CB2D-375D-41F2-BA32-43986A67B09DQ36210704-023C04EF-FE44-4ACB-8C99-2FB9FFECD6F1Q36297939-164CF0FF-5DB2-49E3-9AC8-FAE53E648477Q36358412-229E42F2-06F6-4EE8-8639-F359D93B29F5Q36386383-18CF9403-CA08-4909-AC25-DB8156491AB5Q36439420-D169FB1C-EA01-442C-9DE5-873C437B74EFQ36473355-64A43588-0A5B-4659-BD5F-75588B34B716
P2860
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
@ast
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
@en
type
label
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
@ast
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
@en
prefLabel
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
@ast
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
@en
P2093
P1476
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
@en
P2093
Ekaterina Bassett
Sharon L Campbell
Stephen G Chaney
P356
10.1016/J.CRITREVONC.2004.08.008
P577
2005-01-01T00:00:00Z